Rani Therapeutics Holdings Inc (NASDAQ:RANI) experienced an 18% jump in its stock price following news that the clinical-stage biotherapeutics company will present preclinical findings on its innovative RaniPill capsule at the upcoming Endocrine Society Annual Meeting (ENDO 2025) in July 2025.
The presentation will highlight data showcasing the bioequivalence between an oral bispecific GLP-1/GLP-2 receptor agonist delivered through Rani’s robotic pill technology and the traditional subcutaneous injection method, tested in canine models. Titled “Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines,” the poster session is scheduled for July 14, 2025.
This update marks a potential breakthrough in Rani’s efforts to advance oral biologics delivery platforms, offering an alternative to injectable drugs that could enhance patient compliance and comfort.
The presentation will be part of the session “Adipose Tissue, Appetite, and Obesity: From Breakthroughs to Real-World Challenges: Navigating Weight Loss, Regain, and Therapeutic Advances II” held at the conference in San Francisco.
Rani Therapeutics continues to develop the RaniPill capsule technology to enable oral administration of biologic therapies and drugs traditionally requiring injections.
Rani Therapeutics Holdings stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.